Clinical outcomes of bortezomib-based desensitization in highly sensitized living and deceased donor kidney transplantation
Kidney Research and Clinical Practice · 01.03.2026 · 45 (2) · 253-262
DOI: 10.23876/j.krcp.24.077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney Research and Clinical Practice, erschienen am 01.03.2026. Verfasst von Hyeran Park und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Rep…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Sensitization acts as an immunological barrier to successful kidney transplantation (KT). We aim to investigate the efficacy and safety of bortezomib-based desensitization (BOZ-DSZ) in both highly sensitized living donor KT (LDKT) and deceased donor KT (DDKT).
Methods
We applied BOZ-DSZ to 20 highly sensitized patients—14 LDKT and six DDKT candidates—and analyzed the change in anti-human leukocyte antigen (HLA) antibody, the success rate of transplantation, and posttransplant outcomes including biopsy-proven allograft rejection (BPAR) rate, infectious complication, and allograft survival.
Results
Among 14 LDKT candidates, the peak mean fluorescence intensity (MFI) level of donor-specific anti-HLA antibody (HLA-DSA) decreased in 10 patients (p < 0.05), and the success rate of KT was 92.9% (13 of 14). Incidence of BPAR within the first posttransplant year was 53.8% (7 of 13), and all such cases were rescued by antirejection treatment. One case resulted in mortality due to pneumonia, and there was one allograft failure during the follow-up of 34 months (range, 6–129 months). Among the six DDKT candidates, the peak MFI level of HLA-DSA showed a significant decrease after DSZ in five patients (p = 0.098), and the success rate of KT was 50.0% (3 of 6). One BPAR case (33.3%) occurred within the first posttransplant year and was successfully treated. There was one case of Cytomegalovirus viremia, and there was no allograft failure during the 36-month follow-up (range, 17–42 months).
Conclusion
BOZ-DSZ is effective and safe in terms of successful DSZ, infectious complications, and allograft outcomes for both highly sensitized LDKT and DDKT candidates.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Transplantation Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Nephrology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Nephrology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Zitieren
APA
Park, H., Lee, H., Eum, S. H., Min, J. W., Yoon, H. E., Oh, E. J., Yang, C. W., & Chung, B. H. (2026). Clinical outcomes of bortezomib-based desensitization in highly sensitized living and deceased donor kidney transplantation. Kidney Research and Clinical Practice, 45(2), 253-262. https://doi.org/10.23876/j.krcp.24.077
Vancouver
Park H, Lee H, Eum SH, Min JW, Yoon HE, Oh EJ, et al. Clinical outcomes of bortezomib-based desensitization in highly sensitized living and deceased donor kidney transplantation. Kidney Research and Clinical Practice. 2026;45(2):253-262. doi:10.23876/j.krcp.24.077
BibTeX
@article{Park2026,
author = {Park, Hyeran and Lee, Hanbi and Eum, Sang Hun and Min, Ji-Won and Yoon, Hye Eun and Oh, Eun-Jee and Yang, Chul Woo and Chung, Byung Ha},
title = {Clinical outcomes of bortezomib-based desensitization in highly sensitized living and deceased donor kidney transplantation},
journal = {Kidney Research and Clinical Practice},
year = {2026},
volume = {45},
number = {2},
pages = {253--262},
doi = {10.23876/j.krcp.24.077}
}
EUVIMED